Update on PALLAS international breast cancer study evaluating adjuvant palbociclib

(ECOG-ACRIN Cancer Research Group) The independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) trial determined the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival, following a preplanned interim analysis. No new safety signals were observed in patients receiving palbociclib. PALLAS patients will be counselled by their physicians. All patients will move to protocol-defined extended follow-up. Long-term patient follow-up proceeds as planned.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news